重组人组织型纤溶酶原激酶衍生物溶栓治疗急性心肌梗死疗效及安全性评价

Efficacy and Safety of Reteplase(rPA) for In Jection in the Treatment of Acute Myocardial Infarction

目的研究利用重组人组织型纤溶酶原激酶的衍生物对急性心肌梗死患者进行溶栓治疗的治疗效果,并对其安全性进行评价。方法共选择60例接受溶栓治疗的急性心肌梗死患者进行实验,其中30例患者作为试验组给予重组人组织型纤溶酶原激酶衍生物溶栓治疗,剩余30例患者作为对照组给予尿激酶溶栓治疗,观察两组患者的临床差异。结果试验组患者的治疗效果明显优于对照组患者,血管开通率高、血液流变学指标更接近正常水平、不良反应少。结论对急性心肌梗死患者采用重组人组织型纤溶酶原激酶的衍生物进行溶栓治疗,不仅能有效缓解患者的病情,还能较大程度的减少患者出现不良反应的机率,该治疗方法在临床上具有较大的应用价值。

Objective To evaluate the efficacy of thrombolytic therapy with Reteplase（ rPA） for In Jection in patients with acute myocardial infarction,and to evaluate its safety. Methods A total of 60 patients received thrombolytic therapy in patients with acute myocardial infarction by experiment,including 30 patients as the experimental group received Reteplase for In Jection thrombolysis treatment,the remaining 30 patients as control group received urokinase thrombolytic therapy,and the clinical differences between the two groups were observed. Results The treatment effect of the experimental group was significantly better than that of the control group： the rate of vascular patency was high,the blood rheology index was closer to the normal level,and the adverse reactions were less. Conclusion Thrombolytic therapy in patients with acute myocardial infarction by Reteplase（ rPA） for In Jection,not only can effectively alleviate the patient＇s condition,but also reduce the probability of adverse reactions in patientsto a large extent,and this treatment method has great application value in clinic.